Skip to main content
Top
Literature
2.
go back to reference Warburg O: On the origin of cancer cells. Science. 1956, 123 (3191): 309-314. 10.1126/science.123.3191.309.CrossRefPubMed Warburg O: On the origin of cancer cells. Science. 1956, 123 (3191): 309-314. 10.1126/science.123.3191.309.CrossRefPubMed
3.
go back to reference Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324 (5930): 1029-1033. 10.1126/science.1160809.CrossRefPubMedPubMedCentral Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009, 324 (5930): 1029-1033. 10.1126/science.1160809.CrossRefPubMedPubMedCentral
4.
go back to reference Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012, 21 (3): 297-308. 10.1016/j.ccr.2012.02.014.CrossRefPubMedPubMedCentral Ward PS, Thompson CB: Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012, 21 (3): 297-308. 10.1016/j.ccr.2012.02.014.CrossRefPubMedPubMedCentral
5.
go back to reference Lunt SY, Vander Heiden MG: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011, 27: 441-464. 10.1146/annurev-cellbio-092910-154237.CrossRefPubMed Lunt SY, Vander Heiden MG: Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011, 27: 441-464. 10.1146/annurev-cellbio-092910-154237.CrossRefPubMed
6.
go back to reference Hensley CT, Wasti AT, DeBerardinis RJ: Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013, 123 (9): 3678-3684. 10.1172/JCI69600.CrossRefPubMedPubMedCentral Hensley CT, Wasti AT, DeBerardinis RJ: Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013, 123 (9): 3678-3684. 10.1172/JCI69600.CrossRefPubMedPubMedCentral
7.
go back to reference Weinberg F, Hamanaka R, Wheaton W, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu G, Budinger G, Chandel N: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010, 107 (19): 8788-8793. 10.1073/pnas.1003428107.CrossRefPubMedPubMedCentral Weinberg F, Hamanaka R, Wheaton W, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu G, Budinger G, Chandel N: Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010, 107 (19): 8788-8793. 10.1073/pnas.1003428107.CrossRefPubMedPubMedCentral
8.
go back to reference Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, Rabinowitz JD: Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. 2013, 9: 712-CrossRefPubMedPubMedCentral Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, Shlomi T, Rabinowitz JD: Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol. 2013, 9: 712-CrossRefPubMedPubMedCentral
9.
10.
go back to reference Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, Huang J, Asplund A, Mootha VK: Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Comm. 2014, 5: 3128- Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, Huang J, Asplund A, Mootha VK: Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Comm. 2014, 5: 3128-
11.
go back to reference Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014, 3: e02242-10.7554/eLife.02242.CrossRefPubMedPubMedCentral Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, Chandel NS: Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014, 3: e02242-10.7554/eLife.02242.CrossRefPubMedPubMedCentral
Metadata
Title
Mitochondria and cancer
Author
Navdeep S Chandel
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer & Metabolism / Issue 1/2014
Electronic ISSN: 2049-3002
DOI
https://doi.org/10.1186/2049-3002-2-8

Other articles of this Issue 1/2014

Cancer & Metabolism 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine